Calcium%252520channel%252520blockers

# Calcium Channel Blockers (CCBs) ## Overview Calcium channel blockers (CCBs) inhibit the influx of extracellular calcium ions through L-type voltage-gated calcium channels in vascular smooth muscle and cardiac tissue. They are categorized into **dihydropyridines (DHPs)**, which primarily cause systemic vasodilation, and **non-dihydropyridines (non-DHPs)**, which possess significant negative chronotropic and inotropic effects. ## Primary Indications * **DHPs (e.g., Amlodipine, Nifedipine):** Hypertension, chronic stable angina, Prinzmetal’s angina. * **Non-DHPs (e.g., Diltiazem, Verapamil):** Hypertension, angina, supraventricular tachyarrhythmias (atrial fibrillation/flutter), rate control. ## Adult Dosing * **Amlodipine:** 2.5–10 mg PO once daily (Max: 10 mg/day). * **Nifedipine ER:** 30–90 mg PO once daily (Max: 90 mg/day). * **Diltiazem (IR/ER):** 120–360 mg/day in divided doses or once daily depending on formulation (Max: 360–480 mg/day). * **Verapamil (IR/ER):** 80–320 mg/day in divided doses or once daily (Max: 480 mg/day). * *Note: Dosing varies significantly by indication; consult institutional protocols for acute IV administration (e.g., Diltiazem drip titration).* ## Pediatric Dosing * **Amlodipine:** 0.1 mg/kg/day (start) up to 0.6 mg/kg/day (Max: 10 mg/day). * **Nifedipine:** 0.25–0.5 mg/kg per dose (Max: 20–30 mg/dose). * **Diltiazem/Verapamil:** Often off-label; dosing is highly individualized based on age, weight, and arrhythmia severity. Seek specialist consult (pediatric cardiology). ## Dose Adjustments * **Hepatic Impairment:** Reduce initial doses for Diltiazem, Verapamil, and Amlodipine due to extensive hepatic metabolism. * **Renal Impairment:** Generally no dose adjustment required for CCBs, but monitor for increased sensitivity to hypotensive effects. ## Contraindications * **Non-DHPs:** Severe bradycardia, second- or third-degree AV block (without a pacemaker), sick sinus syndrome, HFrEF (decompensated heart failure), and hypotension. * **General:** Known hypersensitivity to the specific agent. ## Adverse Effects * **DHPs:** Peripheral edema (dose-dependent), reflex tachycardia, flushing, headache, gingival hyperplasia. * **Non-DHPs:** Bradycardia, AV block, constipation (especially Verapamil), worsening of heart failure, dizziness. ## Key Drug Interactions * **CYP3A4 Inhibitors/Inducers:** Levels of most CCBs are significantly altered by inhibitors (e.g., clarithromycin, grapefruit juice) or inducers (e.g., rifampin). * **Beta-Blockers:** Increased risk of additive bradycardia and heart block with non-DHP CCBs. * **Statins:** Diltiazem and Verapamil can increase systemic exposure to Simvastatin and Lovastatin; cap Simvastatin dose at 20 mg/day. * **Digoxin:** Verapamil can significantly increase digoxin serum concentrations. ## Monitoring * **Blood Pressure:** Monitor for hypotension or orthostasis. * **Heart Rate/ECG:** Mandatory for non-DHPs (PR interval monitoring). * **Edema:** Peripheral edema assessment for DHPs. * **Cardiac Function:** Assess for signs of worsening heart failure (dyspnea, weight gain). ## Clinical Pearls * **Edema Management:** DHP-induced peripheral edema is a result of precapillary vasodilation; adding an ACE inhibitor or ARB may help mitigate this by triggering post-capillary venodilation. * **Constipation:** Verapamil is a potent constipator; ensure adequate fiber and fluid intake. * **Switching:** Never switch between IR and ER formulations blindly; pharmacokinetics vary wildly. * **Non-DHPs in HFrEF:** Strictly avoid in patients with heart failure with reduced ejection fraction due to negative inotropic effects. *** **Educational Disclaimer:** This information is for educational purposes only and does not replace professional clinical judgment. Always verify current prescribing information, institutional guidelines, and drug-specific package inserts before administration.